In a previous blog on the use of psychedelics to treat mental health disorders, we reported that the US Food and Drug Administration (FDA) granted breakthrough therapy designation to MDMA (a.k.a., ecstasy) in 2017 as part of...more
In August of 2017, the FDA granted breakthrough therapy designation to MDMA (a.k.a., Ecstasy/Molly) for the treatment of Post-Traumatic Stress Disorder (PTSD). Just recently the results of the first Phase 3 clinical trial...more
Although many states have legalized marijuana for medicinal and/or recreational use, when it comes to using marijuana in a research setting, sources have been very limited. The US Drug Enforcement Administration (DEA) has...more
6/24/2021
/ Agribusiness ,
Cannabis Products ,
Clinical Trials ,
DEA ,
Essential Health Benefits ,
Marijuana ,
Marijuana Cultivation ,
Memorandum of Agreement ,
NIDA ,
Research and Development ,
Scientific Research